EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways

Vandana Pathak, Claudia Arredondo Pimentel, Elli Cooney, Brian Abbott, Jacqueline M Kline

Therapeutic Innovation & Regulatory Science · 2025

DOI: 10.1007/s43441-025-00809-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Vandana Pathak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Regulatory Affairs (Oncology), Amgen Inc, Thousand Oaks, USA. Hauptthemen laut MEDLINE: Drug Approval, Lung Neoplasms, Antibodies, Bispecific, Small Cell Lung Carcinoma. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On May 16, 2024, tarlatamab-dlle (IMDELLTRA®) received approval as the first FDA DLL3 targeting bispecific T-cell engager (BiTE®) therapy indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. This case study provides insights into the regulatory mechanisms, including global expedited pathways, special designations, and US FDA's Oncology Center of Excellence initiatives, which played a key role in the expedited development, review, and approval of the tarlatamab marketing authorization application (MAA) globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalLung NeoplasmsAntibodies, BispecificSmall Cell Lung CarcinomaAntineoplastic AgentsHumansUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

Expedited regulatory pathwaysMarketing authorization applicationProject confirmProject optimusProject orbisRegulatory approvalTarlatamab

Substanzen

Antibodies, BispecificAntineoplastic Agents

Autor:innen und Institutionen

  • Global Regulatory Affairs (Oncology), Amgen Inc, Thousand Oaks, USA.
  • Global Regulatory Affairs (Oncology), Amgen Inc, Thousand Oaks, USA. carredon@amgen.com.

Zitieren

APA

Pathak, V., Pimentel, C. A., Cooney, E., Abbott, B., & Kline, J. M. (2025). The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00809-8

Vancouver

Pathak V, Pimentel CA, Cooney E, Abbott B, Kline JM. The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00809-8

BibTeX
@article{Pathak2025,
  author = {Pathak, Vandana and Pimentel, Claudia Arredondo and Cooney, Elli and Abbott, Brian and Kline, Jacqueline M},
  title = {The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  doi = {10.1007/s43441-025-00809-8}
}
Kostenlos starten →